Search

Your search keyword '"Huang, Yanjuan"' showing total 183 results
Start Over Author "Huang, Yanjuan"
183 results on '"Huang, Yanjuan"'

3. Evaluating the efficacy and safety of perianal injection of liposomal ropivacaine HR18034 for postoperative analgesia following hemorrhoidectomy: A multicenter, randomized, double-blind, controlled phase II clinical trial

Author

Li, Qiuwen, Xu, Shouyu, Ou, Yangwen, Zhou, Lianbang, Huang, Furong, Jiang, Wanwei, Xie, Haihui, Zou, Xiaohua, Gao, Jihua, Jin, Shu'’an, Zhou, Hongmei, Huang, Yanjuan, Pan, Zhihao, Liu, Juying, Wang, Guyan, Li, Xiangkui, Sun, CanLin, Zhao, Ling, Li, Lin, Liu, Qin, Duan, Kaiming, and Wang, Saiying

Published
2024
Full Text
View/download PDF

28. Remimazolam versus propofol for deep sedation/anaesthesia in upper gastrointestinal endoscopy in elderly patients: A multicenter, randomized controlled trial

Author

Lu, Kejian, primary, Wei, Shanshan, additional, Ling, Wenwen, additional, Wei, Yanxia, additional, Ran, Xuelian, additional, Huang, Huageng, additional, Wang, Meixu, additional, Wei, Ning, additional, Liao, Yanying, additional, Qin, Zailing, additional, Pan, Meitao, additional, Wei, Qimei, additional, Fu, Liuhui, additional, Xiong, Boquan, additional, Ma, Chendong, additional, Jiang, Jun, additional, and Huang, Yanjuan, additional

Published
2022
Full Text
View/download PDF

33. Fibroblast activation protein α activatable theranostic pro-photosensitizer for accurate tumor imaging and highly-specific photodynamic therapy

Author

Luo, Yong, primary, Zeng, Zishan, additional, Shan, Ting, additional, Xu, Xiaoyu, additional, Chen, Jie, additional, He, Yuanfeng, additional, Zhang, Tao, additional, Huang, Zeqian, additional, Chai, Guihong, additional, Huang, Yanjuan, additional, Zhao, Yanfang, additional, and Zhao, Chunshun, additional

Published
2022
Full Text
View/download PDF

37. Reduction-responsive dehydroepiandrosterone prodrug nanoparticles loaded with camptothecin for cancer therapy by enhancing oxidation therapy and cell replication inhibition

Author

Xu, Congjun, primary, Yang, Haolan, additional, Xiao, Zhanghong, additional, Zhang, Tao, additional, Guan, Zilin, additional, Chen, Jie, additional, Lai, Hualu, additional, Xu, Xiaoyu, additional, Huang, Yanjuan, additional, Huang, Zeqian, additional, and Zhao, Chunshun, additional

Published
2021
Full Text
View/download PDF

38. A novel recombinant human Frizzled-7 protein exhibits anti-tumor activity against triple negative breast cancer via abating Wnt/beta-catenin pathway

Author

Zhang Kunchi, Zhaoli Zhou, Wei Xie, Yuan He, Gang Huang, Yan Zhang, Huang Yanjuan, Guoqing Wan, and Jin Wang

Subjects
0301 basic medicine, Frizzled, Angiogenesis, INVASION, Antineoplastic Agents, Triple Negative Breast Neoplasms, medicine.disease_cause, Biochemistry, Anti-tumor, DISEASE, Triple negative breast cancer (TNBC), 03 medical and health sciences, 0302 clinical medicine, Anti-angiogenesis, TUMOR, In vivo, Cell Line, Tumor, HEPATOCELLULAR-CARCINOMA, WNT PATHWAY, medicine, Humans, Wnt Signaling Pathway, beta Catenin, Triple-negative breast cancer, Frizzled-7 (Fzd7), Wnt/beta-catenin pathway, Chemistry, Wnt signaling pathway, Cell Biology, Frizzled Receptors, Recombinant Proteins, Neoplasm Proteins, POTENTIAL THERAPEUTIC TARGET, 030104 developmental biology, 030220 oncology & carcinogenesis, Catenin, Cancer research, GROWTH, Female, SIGNALING PATHWAY, Signal transduction, Carcinogenesis, STEM-CELLS, RESISTANCE
Abstract

Triple negative breast cancer (TNBC) is one of the most difficult malignancy to treat due to a lack of targeted therapy. Studies have demonstrated that the activation of Wnt/beta-catenin signaling was preferentially found in TNBC. Frizzled-7 (Fzd7), one of the Wnt receptors, was significantly up-regulated in TNBC and modulated TNBC tumorigenesis through the Wnt signaling pathway, indicating Fzd7 is a biomarker and a potential therapeutic target for TNBC. Here, we designed a recombinant soluble peptide fragment (rhFzd7) to antagonize Fzd7 by competitively binding with Wnt ligands. We demonstrated the ability of rhFzd7 to bind to its ligand, Wnt3a, and monitored the kinetic process using a Biacore X100 system. In addition, the anti-tumor and anti-angiogenic activity of rhFzd7 were studied in vitro and in vivo. Results showed that the purified rhFzd7 pulled down Wnt3a from MDA-MB-231 cells and exhibited high affinity with Wnt3a (KD: 3.41 x 10(-8) M). The data in vitro revealed that rhFzd7 inhibited proliferation and invasion of TNBC cells, and induced apoptosis of TNBC cells effectively. The anti-angiogenic assay indicated that rhFzd7 repressed TNBC angiogenesis in vitro and in vivo. Furthermore, the study in vivo showed that rhFzd7 could sensitize TNBC cells to the anti-tumor effect of Docetaxel. In conclusion, the generation of rhFzd7 lays foundation for the screening of anti-Fzd7 antibody, and this novel design provides an effective candidate for the clinical treatment of TNBC.

Published
2018

40. Oxymatrine enhanced anti-tumor effects of Bevacizumab against triple-negative breast cancer via abating Wnt/β-Catenin signaling pathway

Author

Xie, Wei, Zhang, Yan, Zhang, Shiwei, Wang, Fengxian, Zhang, Kunchi, Huang, Yanjuan, Zhou, Zhaoli, Huang, Gang, and Wang, Jin

Subjects
Original Article
Abstract

Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), was used in combination with traditional chemotherapy as the first line treatment for metastatic colorectal cancer (mCRC), non-small cell lung cancer (NSCLC) and advanced ovarian cancer. However, it shows limited efficacy for human triple-negative breast cancer (TNBC). Bevacizumab shows potent anti-angiogenesis activity, meanwhile, it also increases invasive and metastatic properties of TNBC cells by activiting Wnt/β-Catenin pathway. To overcome this problem, and fully utilize its potency against cancer, further synergistic strategy is recommended to be developed, especially the concurrent use with those Wnt-targeting agents. Here, by screening a small library of traditional Chinese medicine, we identified a Chinese herb derived Oxymatrine, which could target Wnt/β-Catenin signaling and compromise the oncogenic effects of Bevacizumab. Bevacizumab was validated to induce epithelial-mesenchymal cell transformation (EMT) and cancer stem-like properties of TNBC cells in hypoxia/nutritional stress environment. On the contrary, Oxymatrine reversed the EMT phenotype and depleted the subpopulation of TNBC stem cells induced by Bevacizumab. Oxymatrine enhanced the anti-tumor effects of Bevacizumab in vivo, and holded the potential of reducing the risk of relapse and metastasis by impairing the self-renewal ability of TNBC stem cells. The underlying mechanism was elucidated: Bevacizumab stimulated Wnt/β-Catenin signaling pathway, and Oxymatrine could compromise this effect. On this foundation, factoring into the satisfactory anti-angiogenic activity and low toxicity, Oxymatrine is a good candidate for the synergistic therapy together with Bevacizumab for the treatment of TNBC.

Published
2019

44. Exosome‐Coated Zeolitic Imidazolate Framework Nanoparticles for Intracellular Detection of ATP†.

Author

Lv, Wenxing Please verify that the linked ORCID identifiers are correct for each author. The ORCID ID for 'Liang Yin' seems to be invalid. Please check and supply the correct ORCID ID. --> Please confirm that given names (blue) and surnames/family names (verm, Han, Ziwei, Li, Yike, Huang, Yanjuan, Sun, Jiashu, Lu, Xiaoquan, and Liu, Chao

Subjects
ADENOSINE triphosphate, CELL imaging, NANOPARTICLES, METAL-organic frameworks, MICROFLUIDIC devices, FOAM, COORDINATION polymers
Abstract

Main observation and conclusion: The intracellular delivery of metal‐organic frameworks (MOFs) encapsulated with functional biomolecules represents a promising avenue in the field of biomedicine and biosensing. To improve the cellular uptake efficiency of MOFs, here we report the fabrication of cancer cell‐derived exosome membrane (EM)‐coated zeolitic imidazolate framework‐8 (EM‐ZIF‐8) nanoparticles by using a microfluidic sonication device. EM‐ZIF‐8 nanoparticles loaded with FITC‐labeled bovine serum albumin (BSA) can be taken up by cancer cells and evade phagocytosis more efficiently than their counterparts (ZIF‐8 nanoparticles). Moreover, we use EM‐ZIF‐8 loaded with Rhodamine B (RhB) for in situ imaging of cellular adenosine triphosphate (ATP). The shield effect of ZIF‐8 suppresses the fluorescence of RhB, and the presence of ATP disrupts the ZIF‐8 structure based on the competitive coordination between ATP and Zn2+, leading to the restoration of RhB fluorescence. This method allows accurate detection of the fluctuation of ATP in A549 cells induced by Ca2+ or 2‐DDG treatment. The devised biomimetic EM‐ZIF‐8 nanoparticles thus provide an efficient platform for intracellular drug delivery and ATP sensing. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

46. m1A Regulator TRMT10C Predicts Poorer Survival and Contributes to Malignant Behavior in Gynecological Cancers.

Author

Wang, Qingying, Zhang, Qinyi, Huang, Yanjuan, and Zhang, Jiawen

Subjects
CANCER, RNA modification & restriction, CERVICAL cancer, OVARIAN cancer, CELL migration
Abstract

N1-methyladenosine (m1A) is an important post-transcriptional modification in RNA, and plays critical roles in cellular functions. However, the relationship between m1A regulators and clinical significance of gynecological cancers remains unknown. In this study, we systematically analyzed RNA-seq and clinical data from several public database. Cell proliferation and migration assays were performed to verify the function of the m1A writer TRMT10C in cancer cells. We observed genetic alterations and dysregulated expressions of m1A regulators in gynecological cancer samples. We demonstrated that several m1A regulators could serve as prognostic biomarkers for gynecological cancer patients. The high correlations among the expression of m1A, N6-methyladenosine (m6A), and 5mC regulators were also revealed. Gene set enrichment analysis indicated that the mechanism of TRMT10C in regulating tumorigenesis was related to a variety of cancer-related pathways. Moreover, silencing TRMT10C suppressed the proliferation, colony formation, and migration of ovarian cancer and cervical cancer cells. In summary, our results highlight the importance of m1A regulators in regulating oncogenesis, and indicate that targeting specific m1A regulators might be a potential therapeutic strategy for gynecological cancers. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results